A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Transplantation Bookmark and Share

Hematopoietic Cell Transplantation

Our Approach
 
City of Hope’s Hematopoietic Cell Transplantation (HCT) program is one of the largest and most successful transplant centers in the world. As a pioneer in creating breakthrough treatments for all hematologic cancers and blood-related disorders, City of Hope’s Department of Hematology and Hematopoietic Cell Transplantation (HCT) is a world leader in setting standards for stem cell transplantation and in improving long-term outcomes for both children and adults.
 
A Commitment to Care
 
Since City of Hope performed its first bone marrow transplant in 1976, more than 11,000 transplants have been completed for patients from virtually every state and around the world. City of Hope’s HCT program is dedicated to the traditional and newer uses of this procedure. Specialists at City of Hope lead the field of stem cell transplantation with excellent outcomes.Transplant patients at City of Hope have ranged  from younger than one to 79 years old.
 
Hematopoietic cell transplantation (HCT) and peripheral blood stem cell transplantation (PBSCT) use stem cells (immature blood cells) as part of the treatment of a bone marrow disorder. HCT results in the replacement of a patient’s immune system with that of a healthy donor. City of Hope performs both allogeneic (donor) and autologous (from the patient) stem cell transplants.
 
City of Hope is renowned for developing innovative transplant regimens that have improved the cure rate for patients with:
 
  • Acute myelogenous leukemia
  • Acute lymphoblastic leukemia
  • Hodgkin’s lymphoma
  • Lymphoma
  • Multiple myeloma
  • Myelodysplasia
  • Other hematologic disorders
 
Long-term Follow-up Program
City of Hope recognizes the importance of maintaining contact with all transplant patients. Our transplant program established a formal Long-term Follow-up Program in 1998 that follows all patients who have received a transplant at City of Hope. The Long-term Follow-up Program helps researchers compile data on long-term outcomes to increase awareness of the kinds of problems, both physical and psychological, that some patients face after transplant, so patients can receive continuing advice, information and care.
 
A Commitment to Create
 
A major focus for City of Hope researchers has been creating ways to reduce the incidence of major transplant risks such as infection and relapse. They publish their results in prominent peer-reviewed medical journals.
 
Nonmyeloablative (Mini) Transplants
One of these innovative protocols, nonmyeloablative transplants, has allowed patients who could not tolerate the traditional pre-transplant regiments to become candidates for the procedure.
 
Originally, pre-transplant protocols required high-dose chemotherapy and/or high-dose whole-body irradiation. For elderly patients or patients with other diseases, these protocols were too demanding and often excluded them from transplants. In order to improve both the safety of transplantation and its applicability to a larger number of patients, City of Hope developed an approach in 1998 for a “mini” transplant. These transplants rely less on the heavy doses of chemotherapy and radiation and more on the antitumor effects of the graft itself (known as a graft-versus-tumor effect). This novel approach has allowed for transplants in patients who are older, including patients in their 70s, who would previously not have been eligible for a transplant. These patients, with conditions such as leukemia, myeloma, lymphoma and myelodysplasia, have been significantly helped – even cured – by mini transplants.
 
About the Program
 
City of Hope’s Hematopoietic Cell Transplantation Program is accredited by the Foundation for the Accreditation of Cellular Therapy (FACT), the gold standard of excellence for blood and bone marrow transplant programs in the United States.
 
SPORE Grant
The City of Hope Hematologic Neoplasia Program was awarded a Specialized Program of Research Excellence (SPORE) grant to further its work in utilizing transplant and non-transplant approaches for the treatment of malignant lymphoma and Hodgkin lymphoma. This SPORE is one of only three SPORE awards granted in the United States and builds upon the expertise in the transplant and cancer immunotherapy programs at City of Hope.
 
National Cancer Institute Project Grant
The City of Hope’s HCT Program has been continuously funded for nearly 30 years by the National Cancer Institute (NCI) to develop innovative therapies for people battling leukemia, lymphoma and other cancers. The NCI grant supports continuing research aimed at improving the outcome for patients undergoing either autologous or allogeneic transplant for hematologic cancer. The grant also allows researchers at City of Hope to develop laboratory-based clinical studies to extend the boundaries of HCT into new areas. These studies include the development of therapies incorporating the emerging sciences of gene transfer, molecular biology, radioimmunotherapy, cellular immunotherapy and genetics into allogeneic and autologous transplant.
 
HCT Partnership
Southern California Kaiser Permanente Medical Center partners with City of Hope to provide stem cell transplantation services to Kaiser Permanente health plan members. Kaiser Permanente patients needing a transplant have their procedures performed at City of Hope. Kaiser Permanente members have full access to City of Hope’s treatment programs, including new therapeutic approaches designed to improve outcomes and cure rates. Physicians from the Kaiser Permanente bone marrow transplant medical group are members of the City of Hope HCT program and work side-by-side with City of Hope staff. These physicians are responsible for all Kaiser Permanente patients under one unified program of patient care.
 
“Celebration of Life” Bone Marrow Transplant / HCT Reunion
Each year, City of Hope invites bone marrow / hematopoietic cell transplant recipients and their families to attend the “Celebration of Life” event on the Duarte campus. More than 6,500 people from all over the United States and overseas attend the event. The reunion is a joyous day for everyone in attendance — physicians, nurses and former patients — as they celebrate the victories they have attained in fighting cancer.

Transplantation

Hematopoietic Cell Transplantation

Our Approach
 
City of Hope’s Hematopoietic Cell Transplantation (HCT) program is one of the largest and most successful transplant centers in the world. As a pioneer in creating breakthrough treatments for all hematologic cancers and blood-related disorders, City of Hope’s Department of Hematology and Hematopoietic Cell Transplantation (HCT) is a world leader in setting standards for stem cell transplantation and in improving long-term outcomes for both children and adults.
 
A Commitment to Care
 
Since City of Hope performed its first bone marrow transplant in 1976, more than 11,000 transplants have been completed for patients from virtually every state and around the world. City of Hope’s HCT program is dedicated to the traditional and newer uses of this procedure. Specialists at City of Hope lead the field of stem cell transplantation with excellent outcomes.Transplant patients at City of Hope have ranged  from younger than one to 79 years old.
 
Hematopoietic cell transplantation (HCT) and peripheral blood stem cell transplantation (PBSCT) use stem cells (immature blood cells) as part of the treatment of a bone marrow disorder. HCT results in the replacement of a patient’s immune system with that of a healthy donor. City of Hope performs both allogeneic (donor) and autologous (from the patient) stem cell transplants.
 
City of Hope is renowned for developing innovative transplant regimens that have improved the cure rate for patients with:
 
  • Acute myelogenous leukemia
  • Acute lymphoblastic leukemia
  • Hodgkin’s lymphoma
  • Lymphoma
  • Multiple myeloma
  • Myelodysplasia
  • Other hematologic disorders
 
Long-term Follow-up Program
City of Hope recognizes the importance of maintaining contact with all transplant patients. Our transplant program established a formal Long-term Follow-up Program in 1998 that follows all patients who have received a transplant at City of Hope. The Long-term Follow-up Program helps researchers compile data on long-term outcomes to increase awareness of the kinds of problems, both physical and psychological, that some patients face after transplant, so patients can receive continuing advice, information and care.
 
A Commitment to Create
 
A major focus for City of Hope researchers has been creating ways to reduce the incidence of major transplant risks such as infection and relapse. They publish their results in prominent peer-reviewed medical journals.
 
Nonmyeloablative (Mini) Transplants
One of these innovative protocols, nonmyeloablative transplants, has allowed patients who could not tolerate the traditional pre-transplant regiments to become candidates for the procedure.
 
Originally, pre-transplant protocols required high-dose chemotherapy and/or high-dose whole-body irradiation. For elderly patients or patients with other diseases, these protocols were too demanding and often excluded them from transplants. In order to improve both the safety of transplantation and its applicability to a larger number of patients, City of Hope developed an approach in 1998 for a “mini” transplant. These transplants rely less on the heavy doses of chemotherapy and radiation and more on the antitumor effects of the graft itself (known as a graft-versus-tumor effect). This novel approach has allowed for transplants in patients who are older, including patients in their 70s, who would previously not have been eligible for a transplant. These patients, with conditions such as leukemia, myeloma, lymphoma and myelodysplasia, have been significantly helped – even cured – by mini transplants.
 
About the Program
 
City of Hope’s Hematopoietic Cell Transplantation Program is accredited by the Foundation for the Accreditation of Cellular Therapy (FACT), the gold standard of excellence for blood and bone marrow transplant programs in the United States.
 
SPORE Grant
The City of Hope Hematologic Neoplasia Program was awarded a Specialized Program of Research Excellence (SPORE) grant to further its work in utilizing transplant and non-transplant approaches for the treatment of malignant lymphoma and Hodgkin lymphoma. This SPORE is one of only three SPORE awards granted in the United States and builds upon the expertise in the transplant and cancer immunotherapy programs at City of Hope.
 
National Cancer Institute Project Grant
The City of Hope’s HCT Program has been continuously funded for nearly 30 years by the National Cancer Institute (NCI) to develop innovative therapies for people battling leukemia, lymphoma and other cancers. The NCI grant supports continuing research aimed at improving the outcome for patients undergoing either autologous or allogeneic transplant for hematologic cancer. The grant also allows researchers at City of Hope to develop laboratory-based clinical studies to extend the boundaries of HCT into new areas. These studies include the development of therapies incorporating the emerging sciences of gene transfer, molecular biology, radioimmunotherapy, cellular immunotherapy and genetics into allogeneic and autologous transplant.
 
HCT Partnership
Southern California Kaiser Permanente Medical Center partners with City of Hope to provide stem cell transplantation services to Kaiser Permanente health plan members. Kaiser Permanente patients needing a transplant have their procedures performed at City of Hope. Kaiser Permanente members have full access to City of Hope’s treatment programs, including new therapeutic approaches designed to improve outcomes and cure rates. Physicians from the Kaiser Permanente bone marrow transplant medical group are members of the City of Hope HCT program and work side-by-side with City of Hope staff. These physicians are responsible for all Kaiser Permanente patients under one unified program of patient care.
 
“Celebration of Life” Bone Marrow Transplant / HCT Reunion
Each year, City of Hope invites bone marrow / hematopoietic cell transplant recipients and their families to attend the “Celebration of Life” event on the Duarte campus. More than 6,500 people from all over the United States and overseas attend the event. The reunion is a joyous day for everyone in attendance — physicians, nurses and former patients — as they celebrate the victories they have attained in fighting cancer.
Quick Links
 
Why City of Hope
Stephen J. Forman, Francis and Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation, talks about why City of Hope is a special place for cancer treatment.
 
Hematologic Cancers Support Groups
The focus of the Division of Hematopoietic Stem Cell and Leukemia Research is to improve the understanding of leukemia stem cells in order to develop cures for leukemia and other hematologic malignancies.
NEWS & UPDATES
  • Beyond the pink ribbons, special product fundraisers, and the pastel sea of color that marks October, Breast Cancer Awareness Month offers a reason to celebrate and to reflect. More than 2.8 million breast cancer survivors live in the U.S. They are survivors of the second most-common cancer in women, behind ski...
  • Gliomas, a type of tumor that grows in the brain, are very difficult to treat successfully due to their complex nature. That might not always be the case. First some background: The most aggressive and common type of primary brain tumor in adults is glioblastoma. Although the brain tumor mass can often be remov...
  • Cutaneous T cell lymphomas are types of non-Hodgkin lymphoma that arise when infection-fighting white blood cells in the lymphatic system – called lymphocytes – become malignant and affect the skin. The result is rashes and, sometimes, tumors, which can be mistaken for other dermatological conditions. In a smal...
  • Weighing your breast cancer risk? One study suggests a measure to consider is skirt size. A British study suggests that for each increase in skirt size every 10 years after age 25, the five-year risk of developing breast cancer postmenopause increases from one in 61 to one in 51 – a 77 percent increase in risk....
  • Runners prize medals for 5Ks and marathons. Becky Stokes has a medal she cherishes from a very different kind of race: the marathon of treatments necessary to beat her aggressive triple-negative breast cancer. Just a week ago, she completed her last radiation treatment, and danced in the hospital with the staff...
  • Rob Darakjian was diagnosed with acute lymphoblastic leukemia at just 19 years old. He began chemotherapy and was in and out of the hospital for four months. After his fourth round of treatment, he received a bone marrow transplantation from an anonymous donor. Today, he’s cancer free. Darakjian’s s...
  • The environment plays a role in causing cancer – this much we know. But scientists are still trying to understand what that role is, what environmental factors are in play and how precisely those factors are linked to cancer. Now City of Hope researchers have unlocked a clue as to how one carcinogen triggers ca...
  • Jonathan Yamzon, M.D., assistant clinical professor of surgery in the Division of Urology and Urologic Oncology, explains his approach to what’s known as “active surveillance” of men with prostate cancer. Patients need to be educated about their treatment options, he writes. Active surveillanc...
  • For most prostate cancer patients, surgery or radiation therapy is the initial and primary treatment against the disease. But some patients can benefit from chemotherapy and hormone therapy too, especially if there are signs of a relapse or if the cancer has spread beyond the prostate gland. Here, Cy Stein, M.D...
  • Cancer research has yielded scientific breakthroughs that offer patients more options, more hope for survival and a higher quality of life than ever before. The 14.5 million cancer patients living in the United States are living proof that cancer research saves lives. Now, in addition to the clinic, hospital an...
  • Advances in cancer treatment, built on discoveries made in the laboratory then brought to the bedside, have phenomenally changed the reality of living with a cancer diagnosis. More than any other time in history, people diagnosed with cancer are more likely to survive and to enjoy a high quality of life. Howeve...
  • While health care reform has led to an increase in the number of people signing up for health insurance, many people remain uninsured or are not taking full advantage of the health benefits they now have. Still others are finding that, although their premiums are affordable, they aren’t able to see the do...
  • Kidney cancer rates and thyroid cancer rates in adults have continued to rise year after year. Now a new study has found that incidence rates for these cancers are also increasing in children — particularly in African-American children. The study, published online this month in Pediatrics, examined childhood ca...
  • Thyroid cancer has become one of the fastest-growing cancers in the United States for both men and women. The chance of being diagnosed with the cancer has nearly doubled since 1990. This year an estimated 63,000 people will be diagnosed with thyroid cancer in the United States and nearly 1,900 people will die ...
  • Older teenagers and young adults traditionally face worse outcomes than younger children when diagnosed with brain cancer and other central nervous system tumors. A first-of-its-kind study shows why. A team of researchers from the departments of Population Sciences and Pathology at City of Hope recently examine...